Future Evolution of Expedited Pathways for Next Generation CGT Technologies Future Evolution of Expedited Pathways for Next Generation CGT Technologies Cell and Gene Therapies (CGT) represent a monumental shift in the landscape of medical treatments, offering innovative solutions to previously untreatable conditions. As these therapies progress through development, understanding the regulatory landscape is essential for success. The U.S. FDA has established expedited pathways—specifically, Orphan Designation, the Regenerative Medicine Advanced Therapy (RMAT), and Breakthrough Therapy Designation—to facilitate the development of CGT products. This article outlines these pathways, the criteria for qualification, and the evolving nature of regulatory frameworks in both the…

Templates for High Quality RMAT and Breakthrough Designation Request Packages Introduction to RMAT and Breakthrough Designation for CGT Products The rapid evolution of cell and gene therapies (CGT) presents both opportunities and challenges in regulatory landscapes. The United States Food and Drug Administration (FDA) provides specific provisions meant to expedite the development and review of promising therapies through mechanisms such as the Regenerative Medicine Advanced Therapy (RMAT) designation and the Breakthrough Therapy designation. Understanding the regulatory requirements for these designations is crucial for regulatory, CMC (Chemistry, Manufacturing, and Controls), clinical, and QA leaders focusing on CGT products. The RMAT and…

Risk Management When CGT Assets Fail to Confirm Benefit Under Expedited Paths Understanding the Regulatory Landscape for CGT in the US Cell and Gene Therapy (CGT) products have revolutionized the treatment of various diseases, including those with significant unmet medical needs. The United States Food and Drug Administration (FDA) has established expedited pathways such as Orphan Drug Designation, Regenerative Medicine Advanced Therapy (RMAT), and Breakthrough Therapy Designation to accelerate the approval of promising therapies. Regulatory, CMC, clinical, and QA leaders should understand how these regulatory mechanisms operate and the associated risk management strategies. The orphan designation aims to facilitate the…

Using Designations to Support Financing and Partnership Discussions in Cell and Gene Therapy Introduction to Designations in Cell and Gene Therapy As the landscape of drug development becomes increasingly competitive, cell and gene therapy (CGT) products find themselves navigating a complex regulatory environment. The US Food and Drug Administration (FDA) has established various designations—such as orphan designation, Regenerative Medicine Advanced Therapy (RMAT), and breakthrough therapy designation—that can enhance the development process and support financing discussions and partnerships. Understanding how to leverage these designations can be pivotal for regulatory, Chemistry, Manufacturing, and Controls (CMC), clinical, and Quality Assurance (QA) professionals involved…

Governance for Tracking Designation Milestones and Commitments in CGT Portfolios The rapid evolution of cell and gene therapy (CGT) products poses unique challenges and opportunities for regulatory professionals, particularly in the United States under the jurisdiction of the FDA. With the authorization of several expedited pathways such as orphan designation, RMAT (Regenerative Medicine Advanced Therapy), and breakthrough therapy, effectively managing the milestones and commitments associated with these designations has become paramount. This article serves as a comprehensive guide for regulatory professionals, Clinical, CMC, and QA leaders working on CGT products, illustrating a step-by-step approach to governance in tracking and managing…